A Phase 2 interventional study of Glycerol Phenylbutyrate in SLC6A1, sponsored by Scripps Translational Science Institute. Recruiting at 1 site in United States. Open to participants aged 2 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Scripps Translational Science Institute · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Epilepsies, Myoclonic with a site in United States — 11 open to participants now, 17 under way, 4 of them phase 3. Epilepsies, Myoclonic · United States.
Among the 61 studies in Epilepsies, Myoclonic with a site in United States, this one is the 32nd largest by planned enrollment of the 43 interventional ones that give a count, is one of 4 that started in 2026, is one of 9 in phase 2, reaches primary completion later than 14 of the 16 other live ones, and was the 61st registered.
92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.
Browse Epilepsies, Myoclonic studies →11 of the 61 studies in Epilepsies, Myoclonic with a site in United States are open now. Recruiting first, the newest first:
Ionis Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 2–12
The University of Texas Health Science Center, Houston · Sites in United States
Ages 16+
University of Colorado, Denver · Sites in United States
Ages 12 mo–24 mo
Encoded Therapeutics · Sites in United States, Australia, United Kingdom
Ages 6 mo–17 yrs
Cook Children's Health Care System · Sites in United States
Ages up to 18 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.
This study: 2 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 15 · Phase 3 20 · Phase 4 3
First in 2000; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 31 across 56 interventional studies indexed under Epilepsies, Myoclonic.
Median enrollment 36 across the 43 interventional studies, 58 across the 11 observational. Of the 33 that completed or were terminated, 21 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 61 have an industry lead sponsor. The 10 most frequent:
Scripps Translational Science Institute is the lead sponsor of 53 studies on the registry; 13 are open to participants now.
Scripps Translational Science Institute has 1 study filed under Epilepsies, Myoclonic — fewer than ten, so there is no comparison to draw.
10 of the studies in Epilepsies, Myoclonic with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660394Phase 3Longboard PharmaceuticalsA Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS) | 2026-12-31 |
| NCT06872125Phase 3Stoke Therapeutics, IncA Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome | 2027-03 |
| NCT04462770Phase 3EpygenixA Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome | 2027-04 |
| NCT06908226Phase 3Longboard PharmaceuticalsA Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE) | 2027-11-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 61 studies in Epilepsies, Myoclonic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the feasibility of a site-less (fully remote) clinical trial using phenylbutyrate for SLC6A1-related disorders. Study participants will receive treatment with phenylbutyrate, undergo electroencephalogram (EEG) monitoring, and complete laboratory testing. Caregivers will report seizure frequency, answer questionnaires, and report side effects.
Participants will be randomly assigned to one of two groups. Randomization is stratified by age band (\<7 years vs. ≥7 years) and baseline seizure frequency (≤5 vs. >5 daily seizures). One group will begin treatment immediately; the other group will have a 6-week observation period before starting treatment. All participants will receive phenylbutyrate. Treatment lasts up to 18 weeks with the option to extend for up to 3 years. Follow-up occurs at 18 weeks. If extending treatment, additional follow-up occurs at 6 months, 1 year, and then annually.
Participation is completely voluntary. There is the risk of adverse events from the study drug, phenylbutyrate, including hospitalization from metabolic acidosis. There is the risk of loss of confidentiality of your medical and personal information collected for this study. This study does not replace emergency medical care.
This is a fully remote study. Participants may enroll from any U.S. state. No facility visit is required.
The purpose of this study is to determine whether a site-less (fully remote) clinical trial design, one conducted entirely remotely without a physical clinic site, is feasible for families affected by SLC6A1-related disorders. A secondary purpose is to explore the safety, tolerability, and preliminary effectiveness of phenylbutyrate in this population.
SLC6A1-related disorder is a rare genetic condition that causes epilepsy and intellectual disability. It is caused by variants in the SLC6A1 gene, which encodes a protein called GABA transporter 1 (GAT-1) that helps regulate the brain chemical gamma-aminobutyric acid (GABA). Phenylbutyrate is a medication that is Food and Drug Administration (FDA) -approved for a different condition (urea cycle disorders) and is being studied here for its potential antiseizure effects in SLC6A1-related disorders. Early studies have suggested that phenylbutyrate may reduce seizure frequency in some individuals with this condition, but it has not yet been studied in a controlled clinical trial. This study will help determine whether a larger, controlled trial is feasible using a site-less (fully remote) design and will provide early information about how well phenylbutyrate works and how well it is tolerated in this population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This is a fully remote study. Participants may enroll from any U.S. state. No facility visit is required.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Arm A will receive immediate treatment with phenylbutyrate beginning week 0 through week 18.
Drug: Glycerol Phenylbutyrate
Arm B will have a delayed start with an observation period weeks 0-6 followed by treatment beginning at week 6 through week 18.
Drug: Glycerol Phenylbutyrate
Glycerol phenylbutyrate oral liquid (1.1 g/mL) administered orally three times daily with food or formula, or via gastrostomy or nasogastric tube when clinically indicated. The dose is titrated over 8 weeks from a starting dose of 3.6 mL/m²/day to a target maximum of 11.2 mL/m²/day (12.4 g/m²/day), not to exceed 17.5 mL/day total, based on body surface area. Dose adjustments are made based on tolerability and safety laboratory results. Drug is obtained through self-pay via Cost Plus pharmacy with direct home delivery, or through the participant's health insurance at a designated pharmacy. Other Name(s): Ravicti; glycerol phenylbutyrate oral liquid; GPB; 4-phenylbutyrate; 4-PBA
Recruitment efficiency
Number of participants enrolled and time from first contact to consent, averaged across the enrollment period. Target: ≥20 participants enrolled over 24 months.
Time frame: From study opening through end of enrollment (approximately 2 years)
Protocol adherence: seizure diary completion
Proportion of weekly seizure diary entries completed at scheduled intervals across the 18-week assessment period. Target: ≥80% of scheduled entries completed.
Time frame: Weeks 0-18
Protocol adherence: Electroencephalogram (EEG) completion
Proportion of participants completing baseline, week 6, and 18-week EEG as specified by protocol. Target: ≥80%.
Time frame: Baseline, week 6 and week 18
Protocol adherence: side effect questionnaire completion
Proportion of scheduled side effect questionnaires completed at protocol-specified intervals from treatment initiation through week 18. Target: ≥80%.
Time frame: From treatment initiation through week 18
Protocol adherence: safety laboratory completion
Proportion of participants completing scheduled safety laboratory testing at 6 weeks after treatment initiation. Target: ≥80%.
Time frame: 6 weeks after treatment initiation
Retention
Proportion of enrolled participants completing the 18-week assessment period without voluntary or involuntary withdrawal. Target: ≥80%.
Time frame: Week 18
Caregiver satisfaction: overall satisfaction
Median score on User Experience Questionnaire item Q1 assessing overall satisfaction with remote clinical trial participation. Scale 1-5 (1=very dissatisfied, 5=very satisfied). Target: median ≥4.
Time frame: Week 18
Caregiver satisfaction: acceptability
Proportion of caregivers responding "Yes" to User Experience Questionnaire item Q2 asking whether they would recommend participating in a remote clinical trial to other families. Target: ≥80%.
Time frame: Week 18
Caregiver satisfaction: fit with daily routine
Median score on User Experience Questionnaire item Q3 assessing whether the study fit well into the family's daily routine. Scale 1-5 (1=not at all, 5=completely). Target: median ≥4.
Time frame: Week 18
Caregiver satisfaction: clarity of study procedures
Median score on User Experience Questionnaire item Q4 assessing ease of understanding study procedures and requirements. Scale 1-5 (1=very difficult, 5=very easy). Target: median ≥4.
Time frame: Week 18
Caregiver satisfaction: time burden
Median score on User Experience Questionnaire item Q5 assessing ease of finding time to complete study tasks. Scale 1-5 (1=very difficult, 5=very easy). Target: median ≥4.
Time frame: Week 18
Caregiver satisfaction: study team communication
Median score on User Experience Questionnaire item Q6 assessing clarity and helpfulness of study team communication. Scale 1-5 (1=not at all clear/helpful, 5=extremely clear/helpful). Target: median ≥4.
Time frame: Week 18
Caregiver satisfaction: adequacy of remote safety monitoring
Median score on User Experience Questionnaire item Q7 assessing whether the participant's safety was adequately monitored during the remote trial. Scale 1-5 (1=not at all, 5=completely). Target: median ≥4.
Time frame: Week 18
Caregiver satisfaction: access to medical support
Median score on User Experience Questionnaire item Q8 assessing ease of accessing medical support or advice when needed. Scale 1-5 (1=very difficult, 5=very easy). Target: median ≥4.
Time frame: Week 18
Caregiver satisfaction: Research Electronic Data Capture (REDCap) usability
Median score on User Experience Questionnaire item Q9 assessing comfort using the REDCap platform for study participation. Scale 1-5 (1=very uncomfortable, 5=very comfortable). Target: median ≥4.
Time frame: Week 18
Caregiver satisfaction: instructional video usefulness
Median score on User Experience Questionnaire item Q10 assessing usefulness of instructional videos provided through REDCap. Scale 1-5 (1=not at all useful, 5=extremely useful). Target: median ≥4.
Time frame: Week 18
Caregiver satisfaction: optional phone call helpfulness
Median score on User Experience Questionnaire item Q12 among participants who participated in the optional phone call at 4 weeks after treatment initiation (Q11=Yes). Scale 1-5 (1=not at all helpful, 5=extremely helpful). Proportion participating reported separately. Target: median ≥4 among participants.
Time frame: 4 weeks after treatment initiation
Caregiver experience: facilitators and barriers
Thematic summary of free-text responses to User Experience Questionnaire items Q13 (what participants liked most) and Q14 (challenges faced). Analyzed qualitatively to identify themes relevant to remote trial design.
Time frame: Week 18
Seizure frequency: percent change from baseline
Percent change in average weekly seizure frequency from the baseline observation period to weeks 14-18 of treatment (stable dose period), based on caregiver-completed seizure diaries. Analyzed descriptively.
Time frame: Baseline through week 18
Seizure frequency: responder rate
Proportion of participants achieving ≥50% reduction in average weekly seizure frequency from baseline to the stable dose period (weeks 14-18 of treatment). Analyzed descriptively.
Time frame: Baseline through week 18
Caregiver Global Impression of Change (CGIC)
Caregiver-rated global impression of change since starting phenylbutyrate, assessed using a 7-point scale (1=very much improved, 7=very much worse). Analyzed descriptively.
Time frame: Week 18
Adaptive behavior: Vineland Adaptive Behavior Scales, Third Edition (VABS-3) composite score
Change in VABS-3 Adaptive Behavior Composite score from baseline to week 18. Standard scores range 20-160; higher scores indicate better adaptive functioning. Analyzed descriptively.
Time frame: Baseline and week 18
Behavior: Aberrant Behavior Checklist Community Version
Change in total score and subscale scores (Irritability/Agitation, Lethargy/Social Withdrawal, Stereotypic Behavior, Hyperactivity/Noncompliance, Inappropriate Speech) from baseline to week 18. Total scores range 0-174; higher scores indicate more frequent or severe behavioral difficulties. Analyzed descriptively.
Time frame: Baseline and Week 18
Quality of life: QI-Disability score
Change in Quality of Life Inventory-Disability (QI-Disability) total score from baseline to week 18. Scores range 0-100; higher scores indicate better quality of life. Analyzed descriptively.
Time frame: Baseline and week 18
Medication Burden
Change in the number of concomitant antiseizure medications (not counting glycerol phenylbutyrate) from baseline to week 18, captured via weekly seizure diary. Analyzed descriptively.
Time frame: Baseline and Week 18
Safety and tolerability: adverse events
Frequency and severity of adverse events, serious adverse events, dose interruptions, and discontinuations throughout the study period. Summarized descriptively by event type, severity, causality, and outcome.
Time frame: From treatment initiation through week 18
Safety and tolerability: laboratory values
Proportion of 6 week post-treatment initiation safety laboratory values that are outside pre-specified thresholds reported descriptively, including phenylacetate level \> 500 µg/mL, phenylacetic acid-to-phenylacetylglutamine (PAA-to-PAGN) ratio \> 1.5, bicarbonate level \< 17 mEq/L, anion gap \> 12 mEq/L, urine pH \< 5.5, the combination of low carnitine (total carnitine level \< 30 µmol/L OR free carnitine level \< 20 µmol/L) PLUS an elevated esterified-to-free carnitine ratio \> 0.4, and ALT or AST (exceeds 3× the upper limit of normal with symptoms, or exceeds 5× the upper limit of normal without symptoms). Each parameter is reported separately as the proportion of participants with values outside pre-specified thresholds.
Time frame: 6 weeks after treatment initiation
EEG: Delta spectral power
Change in delta-frequency (2.5-4 Hz) EEG spectral power from baseline to week 18, calculated at 1-second intervals across 18 channel pairs in the double banana montage, averaged across channels and the analyzed epoch. Analyzed descriptively as an exploratory biomarker of treatment response.
Time frame: Baseline and Week 18
EEG: Delta-frequency autocorrelation
Change in EEG autocorrelation at lags corresponding to 2.5-4 Hz from baseline to week 18, calculated at 1-second intervals across 18 channel pairs in the double banana montage, averaged across channels and the analyzed epoch. Analyzed descriptively.
Time frame: Baseline and Week 18
EEG: Spectral entropy
Change in broadband (0-30 Hz) EEG spectral entropy from baseline to week 18, calculated at 1-second intervals across 18 channel pairs in the double banana montage, averaged across channels and the analyzed epoch. Analyzed descriptively.
Time frame: Baseline and Week 18
EEG: Combination of three measures
Proportion of 1-second EEG segments meeting all three pre-specified thresholds simultaneously (delta power \>105,000 μV², autocorrelation \>0.410, spectral entropy ≤3.16) in ≥3 channels, compared from baseline to week 18. Analyzed descriptively as an exploratory biomarker outcome.
Time frame: Baseline and Week 18
Concurrent randomized seizure comparison
Proportion of participants achieving ≥50% seizure reduction in Arm A (on treatment) versus Arm B (observation period) at week 6, reported as absolute risk difference, relative risk reduction, and number needed to treat, with 95% confidence intervals. Quantitative EEG measures (delta-frequency spectral power, autocorrelation at 2.5-4 Hz lags, and broadband spectral entropy) will be compared between arms at week 6 as an exploratory biomarker. Analyzed descriptively.
Time frame: Week 6
Arm A within-person early vs. stable dose seizure comparison
Mean weekly seizure frequency during early treatment (weeks 0-2) compared to the stable dose period (weeks 14-18) in Arm A participants. Analyzed descriptively.
Time frame: Weeks 0-2 and weeks 14-18
Arm B within-person seizure change
Seizure frequency trajectory in Arm B, estimated using a segmented regression model assessing whether the pre-treatment slope is flat and characterizing the post-treatment slope through the stable dose period (weeks 12-18). Analyzed descriptively.
Time frame: Weeks 0-6 and weeks 12-18 of treatment
Trajectory replication across arms
Comparison of post-treatment slopes from the segmented regression model in Arm A and Arm B, offset by 6 weeks, assessing whether the two arms show comparable seizure frequency trajectories following treatment initiation. Analyzed descriptively.
Time frame: Weeks 0-18
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Mar 2029, 29 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycerol phenylbutyrate
Scripps Translational Science Institute